Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is a rare disease that affects the filtering units in your kidneys (glomeruli). There are many types of glomerular diseases.

Pegcetacoplan treatment led to proteinuria reduction and eGFR stabilization across important subgroups with C3 glomerulopathy and IC-MPGN. Pegcetacoplan induces a clinically meaningful ...

STOCKHOLM, Jan. 16, 2026 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients ...

WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) and Sobi ® today announced that positive results from the Phase 3 VALIANT study were presented as an oral ...

C3G and IC-MPGN both cause protein deposits that reduce kidney function. Overactive proteins in the immune system lead to these different conditions. C3G and IC-MPGN are rare kidney conditions. They ...

EMPAVELI shows significant proteinuria reduction and maintains kidney function in patients with C3G and IC-MPGN; safety profile remains consistent. Apellis Pharmaceuticals and Sobi recently presented ...

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI ® (pegcetacoplan) as the ...

No new safety signals were observed New data presented at late-breaking session at the European Renal Association Congress Marketing applications for EMPAVELI are under review with the FDA and EMA In ...

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 ...